Cardiovascular drugs and therapy

GLP-1 Drugs and the Risk of Irregular Heartbeat in Chronic Kidney Disease Patients Not on Dialysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

GLP-1 receptor agonists (GLP-1 RAs) are associated with improved cardiorenal outcomes in chronic kidney disease (CKD) patients.

  • The role of GLP-1 RAs in reducing the risk of atrial fibrillation (AF) in CKD patients without diabetes or obesity is uncertain.
  • Evidence suggests that GLP-1 RAs may benefit patients with obesity or type 2 diabetes.
  • Further investigation is needed to clarify the effects of GLP-1 RAs on AF risk specifically in CKD patients lacking obesity and diabetes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Competing interests: The authors declare no competing interests. Role of Funder/Sponsor Statement: The funder/sponsor did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of data; or the preparation, review, and decision to submit manuscript for publication. Non-Author Contributions to Data Collection, Analysis, or Writing/Editing Assistance: We thank the UAMS Science Communication Group for reviewing the manuscript without compensation. Originality of Content: All information and materials in the manuscript are original.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief